Trial · NCT01598090
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | 51.9 | 95% Confidence Interval 31.9 to 71.3 | Percentage of participants | |
| Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B | Part B: Peginterferon Lambda-1a + RBV + TVR | 76.2 | 95% Confidence Interval 72 to 80.3 | Percentage of participants | |
| Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B | Part B: Peginterferon Alfa-2a + RBV + TVR | 82 | 95% Confidence Interval 76.8 to 87.3 | Percentage of participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | AEs | 26 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | SAEs | 6 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | Drug related AEs | 12 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | Discontinuation due to AEs | 2 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | Death | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | Dose reductions - Lambda | 3 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | Dose reductions - RBV | 7 | Participants | |
| Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | 48.1 | 95% Confidence Interval 28.7 to 68.1 | Percentage of participants | |
| Percentage of Subjects With Sustained Virologic Response at Follow-Up Week 24 (SVR24) - Part A | Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label) | 40.7 | 95% Confidence Interval 22.4 to 61.2 | Percentage of participants | |
| Percentage of Treatment-Naïve Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B | Part B: Peginterferon Lambda-1a + RBV + TVR | 73.6 | 95% Confidence Interval 68.7 to 78.5 | Percentage of participants | |
| Percentage of Treatment-Naïve Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B | Part B: Peginterferon Alfa-2a + RBV + TVR | 81.9 | 95% Confidence Interval 75.9 to 88 | Percentage of participants | |
| Percentage of Participants With Treatment Emergent Cytopenic Abnormalities - Part B | Part B: Peginterferon Lambda-1a + RBV + TVR | 11.7 | 95% Confidence Interval 8.6 to 14.8 | Percentage of participants | |
| Percentage of Participants With Treatment Emergent Cytopenic Abnormalities - Part B | Part B: Peginterferon Alfa-2a + RBV + TVR | 55.8 | 95% Confidence Interval 49 to 62.6 | Percentage of participants | |
| Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part B | Part B: Peginterferon Lambda-1a + RBV + TVR | 64 | 95% Confidence Interval 59.3 to 68.6 | Percentage of participants | |
| Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part B | Part B: Peginterferon Alfa-2a + RBV + TVR | 70.9 | 95% Confidence Interval 64.7 to 77.1 | Percentage of participants | |
| Percentage of Participants With On-Treatment Flu-Like Symptoms And Musculoskeletal Symptoms- Part B | Part B: Peginterferon Lambda-1a + RBV + TVR | Flu-Like Symptoms | 14.4 | 95% Confidence Interval 11 to 17.7 | Percentage of participants |
| Percentage of Participants With On-Treatment Flu-Like Symptoms And Musculoskeletal Symptoms- Part B | Part B: Peginterferon Alfa-2a + RBV + TVR | Flu-Like Symptoms | 36.4 | 95% Confidence Interval 29.8 to 43 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01598090/results